2020
Continuous Ketamine Infusion for Pain as an Opportunity for Psychotherapy for PTSD: A Case Series of Ketamine-Enhanced Psychotherapy for PTSD and Pain (KEP-P2)
Keizer BM, Roache JD, Jones JR, Kalpinski RJ, Porcerelli JH, Krystal JH. Continuous Ketamine Infusion for Pain as an Opportunity for Psychotherapy for PTSD: A Case Series of Ketamine-Enhanced Psychotherapy for PTSD and Pain (KEP-P2). Psychotherapy And Psychosomatics 2020, 89: 326-329. PMID: 32248200, DOI: 10.1159/000507095.Peer-Reviewed Original Research
2019
Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial
Abdallah CG, Roache JD, Averill LA, Young-McCaughan S, Martini B, Gueorguieva R, Amoroso T, Southwick SM, Guthmiller K, López-Roca AL, Lautenschlager K, Mintz J, Litz BT, Williamson DE, Keane TM, Peterson AL, Krystal JH, PTSD F. Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemporary Clinical Trials 2019, 81: 11-18. PMID: 30999057, DOI: 10.1016/j.cct.2019.04.009.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderStudy drugClinical trialsTherapeutic effectPharmacotherapy of PTSDFirst placebo-controlled trialPlacebo-controlled clinical trialActive duty military populationDose-related efficacyMedication treatment optionsPlacebo-controlled trialDose-related effectsNovel neural mechanismActive duty militaryKetamine infusionSerotonergic antidepressantsEligible participantsTreatment optionsCase reportNew drug developmentOnly trialSustained reductionVeteran populationDrug AdministrationPilot evidence
2012
NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia
Anticevic A, Gancsos M, Murray JD, Repovs G, Driesen NR, Ennis DJ, Niciu MJ, Morgan PT, Surti TS, Bloch MH, Ramani R, Smith MA, Wang XJ, Krystal JH, Corlett PR. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2012, 109: 16720-16725. PMID: 23012427, PMCID: PMC3478611, DOI: 10.1073/pnas.1208494109.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlgorithmsBrainCognitionDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleHumansInfusions, IntravenousKetamineMagnetic Resonance ImagingMaleMemoryModels, NeurologicalPattern Recognition, VisualPsychomotor PerformanceReceptors, N-Methyl-D-AspartateSchizophreniaSynaptic TransmissionYoung AdultConceptsNeural systemsLarge-scale brain systemsTask-dependent activationN-methyl-D-aspartate receptorsRealistic computational modelingSevere neuropsychiatric illnessNMDA glutamate receptor antagonistGlutamate receptor antagonistsBrain systemsNMDA receptor functionTask performanceMultiple interacting regionsCognitionCortical disinhibitionGlutamatergic neurotransmissionReceptor antagonistCortical computationGlutamate's roleReciprocal relationshipNeuropsychiatric illnessLocal circuitsReceptor functionSchizophreniaPresent findingsComputational modeling
2011
Intravenous Ethanol Infusion Decreases Human Cortical γ-Aminobutyric Acid and N-Acetylaspartate as Measured with Proton Magnetic Resonance Spectroscopy at 4 Tesla
Gomez R, Behar KL, Watzl J, Weinzimer SA, Gulanski B, Sanacora G, Koretski J, Guidone E, Jiang L, Petrakis IL, Pittman B, Krystal JH, Mason GF. Intravenous Ethanol Infusion Decreases Human Cortical γ-Aminobutyric Acid and N-Acetylaspartate as Measured with Proton Magnetic Resonance Spectroscopy at 4 Tesla. Biological Psychiatry 2011, 71: 239-246. PMID: 21855054, PMCID: PMC3227760, DOI: 10.1016/j.biopsych.2011.06.026.Peer-Reviewed Original ResearchMeSH KeywordsAdultAspartic AcidBreath TestsCerebral CortexDipeptidesEthanolFemaleGamma-Aminobutyric AcidHumansInfusions, IntravenousMagnetic Resonance SpectroscopyMaleConceptsIntravenous ethanol infusionProton magnetic resonance spectroscopyEthanol infusionNAA levelsN-acetylaspartateCortical γ-aminobutyric acidAcute pharmacologic effectsLevels of GABAHealthy social drinkersBreath alcohol levelsN-acetylaspartyl-glutamateCortical GABAEthanol modulatesFirst infusionΓ-aminobutyric acidGABA levelsPharmacologic effectsBrain ethanolOccipital GABAInfusionAlcohol levelsMagnetic resonance spectroscopyReceptor functionBreath ethanolHuman cortex
2008
Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy—a [123I]CNS-1261 SPET study
Stone JM, Erlandsson K, Arstad E, Squassante L, Teneggi V, Bressan RA, Krystal JH, Ell PJ, Pilowsky LS. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy—a [123I]CNS-1261 SPET study. Psychopharmacology 2008, 197: 401-408. PMID: 18176855, DOI: 10.1007/s00213-007-1047-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrief Psychiatric Rating ScaleDose-Response Relationship, DrugGuanidinesHumansInfusions, IntravenousIodine RadioisotopesKetamineMalePrefrontal CortexPsychoses, Substance-InducedReceptors, N-Methyl-D-AspartateSchizophreniaSingle-Blind MethodTomography, Emission-Computed, Single-PhotonConceptsBrief Psychiatric Rating ScaleVolume of distributionNMDA receptorsPsychotic symptomsN-methyl-D-aspartate receptorsKetamine-induced psychotic symptomsSingle photon emission tomographyNMDA receptor bindingEffects of ketamineNegative subscaleHealthy human controlsPsychiatric Rating ScaleNegative psychotic symptomsInferior frontal cortexKetamine administrationBolus infusionHealthy controls
2007
Psychiatric safety of ketamine in psychopharmacology research
Perry EB, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O’Donnell E, Krystal JH, D’Souza D. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 2007, 192: 253-260. PMID: 17458544, DOI: 10.1007/s00213-007-0706-2.Peer-Reviewed Original ResearchConceptsSubanesthetic dosesHealthy human subjectsKetamine administrationClinical research programHuman subjectsTest sessionsPsychotic spectrum disordersPsychiatric safetyResidual sequelaePlacebo infusionIntravenous infusionKetamine effectsPsychopharmacology studiesResultsFour hundredAdverse reactionsObjectiveTo reportHealthy subjectsStudy participationClinical investigationHealthy humansSide effectsKetamineInfusionDosesAdministration
2006
Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects
Neumeister A, Carson R, Henry S, Planeta-Wilson B, Binneman B, Maguire RP, Luckenbaugh DA, D'Souza C, Krystal JH, Frost JJ. Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects. Journal Of Clinical Psychopharmacology 2006, 26: 595-599. PMID: 17110816, DOI: 10.1097/01.jcp.0000245558.14284.aa.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsBehaviorBrainBrain MappingCluster AnalysisCross-Over StudiesDouble-Blind MethodFemaleFluorodeoxyglucose F18GlycineHumansInfusions, IntravenousMagnetic Resonance ImagingMaleNeuropsychological TestsPositron-Emission TomographyRadiopharmaceuticalsReference ValuesSerineConceptsN-methyl-D-aspartate receptor functionReceptor functionRegional cerebral metabolic rateAdministration of glycineCerebral metabolic effectsMagnetic resonance imaging studyPositron emission tomography studyHealthy control subjectsNMDA receptor functionCerebral metabolic rateEmission tomography studiesTest dayHealthy human subjectsResonance imaging studySignificant reductionPositron emission tomographyDorsolateral prefrontal cortexIntravenous glycinePlacebo infusionCerebral metabolismPatient populationControl subjectsGlycine administrationGlycine infusionIntravenous administration
2004
Altered NMDA Glutamate Receptor Antagonist Response in Individuals With a Family Vulnerability to Alcoholism
Petrakis IL, Limoncelli D, Gueorguieva R, Jatlow P, Boutros NN, Trevisan L, Gelernter J, Krystal JH. Altered NMDA Glutamate Receptor Antagonist Response in Individuals With a Family Vulnerability to Alcoholism. American Journal Of Psychiatry 2004, 161: 1776-1782. PMID: 15465973, DOI: 10.1176/ajp.161.10.1776.Peer-Reviewed Original ResearchAdultAffectAlcohol DrinkingAlcoholic IntoxicationAlcoholismBrief Psychiatric Rating ScaleDissociative DisordersDouble-Blind MethodEthanolFamilyFemaleGenetic Predisposition to DiseaseHumansInfusions, IntravenousKetamineMalePedigreePlacebosPsychoses, AlcoholicReceptors, N-Methyl-D-AspartateRisk Factors
2002
Impact of intravenous nicotine on BOLD signal response to photic stimulation
Jacobsen LK, Gore JC, Skudlarski P, Lacadie CM, Jatlow P, Krystal JH. Impact of intravenous nicotine on BOLD signal response to photic stimulation. Magnetic Resonance Imaging 2002, 20: 141-145. PMID: 12034334, DOI: 10.1016/s0730-725x(02)00494-0.Peer-Reviewed Original ResearchMeSH KeywordsHumansInfusions, IntravenousMagnetic Resonance ImagingNicotinePhotic StimulationVisual CortexConceptsBOLD signal responseFunctional magnetic resonance imagingPhotic stimulationIntravenous infusionNeuronal activitySuccessive intravenous infusionsBlood oxygen level-dependent (BOLD) signalEffects of nicotineLevel-dependent signalMagnetic resonance imagingHealthy smokersVascular effectsTobacco smokingBrain effectsNicotine receptorsIntravenous nicotineEvidence of alterationsOccipital cortexVisual cortexResonance imagingNicotineBOLD signalStimulationInfusionCortex
1998
Dose-Related Ethanol-like Effects of the NMDA Antagonist, Ketamine, in Recently Detoxified Alcoholics
Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS. Dose-Related Ethanol-like Effects of the NMDA Antagonist, Ketamine, in Recently Detoxified Alcoholics. JAMA Psychiatry 1998, 55: 354-360. PMID: 9554431, DOI: 10.1001/archpsyc.55.4.354.Peer-Reviewed Original Research
1996
Serotonergic and noradrenergic dysregulation in alcoholism: m- chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects
Krystal JH, Webb E, Cooney NL, Kranzler HR, Southwick SW, Heninger GR, Charney DS. Serotonergic and noradrenergic dysregulation in alcoholism: m- chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. American Journal Of Psychiatry 1996, 153: 83-92. PMID: 8540598, DOI: 10.1176/ajp.153.1.83.Peer-Reviewed Original ResearchConceptsHealthy comparison subjectsAlcoholic patientsComparison subjectsCortisol responseYohimbine infusionPostsynaptic noradrenergic receptorsBlood pressure responseDouble-blind conditionsNoradrenergic reactivitySaline placeboNoradrenergic receptorsMHPG levelsIntravenous infusionYohimbine effectMHPG responsePlasma levelsNoradrenergic systemPersistent alterationsNoradrenergic dysregulationMale inpatientsDrug effectsNeuroendocrine responsivityPatientsPhysiologic responsesPlasma cortisolContinuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. Journal Of Nuclear Medicine 1996, 37: 11-5. PMID: 8543979.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsBenzamidesBrainContrast MediaCorpus StriatumDopamine AntagonistsDose-Response Relationship, DrugFeasibility StudiesHumansInfusions, IntravenousIodine RadioisotopesMalePiperazinesPyrrolidinesReceptors, DopamineReceptors, Dopamine D2Time FactorsTomography, Emission-Computed, Single-PhotonConceptsHealthy male subjectsContinuous infusionBrain activity levelsReceptor occupancyStriatal activityAntipsychotic agentsDopamine receptorsMale subjectsSerial venous blood samplesSide effect ratingsBrain time-activity curvesContinuous intravenous infusionExtrapyramidal side effectsStriatal dopamine receptorsVenous blood samplesDopamine receptor occupancySerial SPECT imagesClinical responseExtrapyramidal symptomsIntravenous infusionSerum prolactinAntipsychotic drugsBlood samplesSide effectsTime-activity curves
1995
Effects of the benzodiazepine antagonist flumazenil in PTSD
Randall P, Bremner J, Krystal J, Nagy L, Heninger G, Nicolaou A, Charney D. Effects of the benzodiazepine antagonist flumazenil in PTSD. Biological Psychiatry 1995, 38: 319-324. PMID: 7495926, DOI: 10.1016/0006-3223(94)00306-n.Peer-Reviewed Original ResearchConceptsVisual analogue rating scaleAdministration of flumazenilAnxiety symptomsCrossover study designBenzodiazepine antagonist flumazenilGABAA receptor complexBenzodiazepine/GABAA receptor complexPanic disorder patientsAnalogue rating scalesFlumazenil administrationPTSD Symptom ScaleIntravenous infusionAntagonist flumazenilGABAA antagonistHealthy controlsClinical studiesDisorder patientsSymptom ScaleFlumazenilPanic disorderPanic attacksVietnam combat veteransStudy designRating ScalePTSD symptoms
1993
Abnormal Noradrenergic Function in Posttraumatic Stress Disorder
Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolaou A, Heninger GR, Charney DS. Abnormal Noradrenergic Function in Posttraumatic Stress Disorder. JAMA Psychiatry 1993, 50: 266-274. PMID: 8466387, DOI: 10.1001/archpsyc.1993.01820160036003.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderYohimbine-induced panic attacksUncontrollable stressStress disorderYohimbine-induced increasesSystolic blood pressureSubgroup of patientsHealthy male subjectsCore PTSD symptomsCardiovascular effectsBlood pressureMale patientsPathophysiological relationshipNoradrenergic functionPreclinical dataNeurobiological sequelaeHealthy subjectsHeart rateNeuronal regulationPanic disorderMale subjectsNeuronal functionPanic attacksPatientsYohimbine hydrochloride
1992
Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients
Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatrica Scandinavica 1992, 86: 273-282. PMID: 1333719, DOI: 10.1111/j.1600-0447.1992.tb03266.x.Peer-Reviewed Original ResearchConceptsPanic disorder patientsDisorder patientsPanic disorderIntravenous yohimbineHealthy subjectsYohimbine-induced panic attacksClonidine-induced decreaseYohimbine-induced increasesGrowth hormone responseNeuronal dysregulationCardiovascular effectsPlasma MHPGPatientsPlasma 3Hormone responseNeuronal functionPanic attacksClonidineHuman dataDisordersYohimbineHuman anxietySubgroupsFear statesFunctional regulation
1990
Opioid antagonist challenges in buprenorphine maintained patients
Kosten T, Krystal J, Charney D, Price L, Morgan C, Kleber H. Opioid antagonist challenges in buprenorphine maintained patients. Drug And Alcohol Dependence 1990, 25: 73-78. PMID: 2323312, DOI: 10.1016/0376-8716(90)90144-4.Peer-Reviewed Original ResearchConceptsSublingual buprenorphine treatmentBlood pressure increaseDouble-blind placeboOpioid withdrawal symptomsBlind placeboIntravenous naloxoneNaltrexone challengeOral naltrexoneLast doseBlood pressureBuprenorphine treatmentPlacebo substitutionMHPG levelsWithdrawal symptomsPlacebo challengeSignificant symptomsAntagonist challengeBuprenorphinePatientsPlaceboNaloxoneSymptomsNaltrexoneDoseMonths
1989
Neuroendocrine and Mood Responses to Intravenous L-Tryptophan in 3,4-Methylenedioxymethamphetamine (MDMA) Users: Preliminary Observations
Price LH, Ricaurte GA, Krystal JH, Heninger GR. Neuroendocrine and Mood Responses to Intravenous L-Tryptophan in 3,4-Methylenedioxymethamphetamine (MDMA) Users: Preliminary Observations. JAMA Psychiatry 1989, 46: 20-22. PMID: 2562914, DOI: 10.1001/archpsyc.1989.01810010022003.Peer-Reviewed Original Research